PlainRecalls
ModerateClass IITerminated

FDA Drug recall · Reported April 26, 2017

Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg triamcinolone acetonide, distributed in a) 15 grams (NDC 51672-1263-1), b) 30 grams (NDC 51672-1263-2) and c) 60 grams (NDC 51672-1263-3) tubes, Rx only, TARO label; Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1 -- Dist. by: Taro Pharmaceuticals U.S.A. Inc., Hawthorne, NY 10532

Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability

Recall #
D-0676-2017
Affected scope
278,304 tubes
Initiated
March 28, 2017
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Taro Pharmaceuticals U.S.A., Inc. recalled Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg tria… - a moderate-severity action.

Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg tria… was recalled by Taro Pharmaceuticals U.S.A., Inc. in April 26, 2017. Reason: Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability. Check the official notice for the remedy. Verify recall #D-0676-2017 with the FDA Drug before acting.

The recall

Taro Pharmaceuticals U.S.A., Inc. issued this moderate-severity FDA Drug recall-Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability.

Moderate
severity level
Class II
classification
April 26, 2017
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0676-2017 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0676-2017) was formally reported on April 26, 2017, with the manufacturer initiating the action on March 28, 2017. It is classified under Moderate severity (Class II), with a current status of Terminated. Taro Pharmaceuticals U.S.A., Inc. is listed as the recalling firm, operating out of Hawthorne, NY. Federal records list the affected scope as 278,304 tubes.

The documented reason for this recall is: Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability Distribution data in the federal record shows the product reached: Nationwide and Puerto Rico. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 3 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Cosmetics & Personal Care recalls over time

Where this recall sits in its category - 1,360 cosmetics & personal care recalls on record

-1000100200300400 20052008201120142017202020232026 22
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Moderate

Affected scope

278,304 tubes

Related Recalls

6

3 from same agency

Product description

Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg triamcinolone acetonide, distributed in a) 15 grams (NDC 51672-1263-1), b) 30 grams (NDC 51672-1263-2) and c) 60 grams (NDC 51672-1263-3) tubes, Rx only, TARO label; Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1 -- Dist. by: Taro Pharmaceuticals U.S.A. Inc., Hawthorne, NY 10532

Reason for recall

Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Terminated
Recall number D-0676-2017
Date reported April 26, 2017
Date initiated March 28, 2017
Recalling firm Taro Pharmaceuticals U.S.A., Inc.
Firm location Hawthorne, NY
Affected scope 278,304 tubes
Distribution Nationwide and Puerto Rico

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0676-2017) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Nystatin and Triamcinolone Acetonide Cream, USP, 100,000 USP nystatin units and 1 mg triamcinolone acetonide, distributed in a) 15 grams (NDC 51672-1263-1), b) 30 grams (NDC 51672-1263-2) and c) 60 grams (NDC 51672-1263-3) tubes, Rx only, TARO label; Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1 -- Dist. by: Taro Pharmaceuticals U.S.A. Inc., Hawthorne, NY 10532. Recalled by Taro Pharmaceuticals U.S.A., Inc.. Units affected: 278,304 tubes.
Why was this product recalled?
Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability
Which agency issued this recall?
This recall was issued by the FDA Drug on April 26, 2017. Severity: Moderate. Recall number: D-0676-2017.
Where was the recalled product distributed?
Distribution: Nationwide and Puerto Rico.
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0676-2017) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with Tiny Land Children's Play Tents Recalled Due to Risk of Inj… →

Browse all Cosmetics & Personal Care recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 26, 2017. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.